BC
ACER

Burleson & Co’s Acer Therapeutics Inc ACER Stock Holding History

Burleson & Co’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$916 Hold
365
– – ﹤0.01% 356
2022
Q3 		$1K Hold
365
– – ﹤0.01% 388
2022
Q2 		$0 Hold
365
– – ﹤0.01% 528
2022
Q1 		$1K Hold
365
– – ﹤0.01% 395
2021
Q4 		$1K Hold
365
– – ﹤0.01% 352
2021
Q3 		$1K Hold
365
– – ﹤0.01% 345
2021
Q2 		$1K Hold
365
– – ﹤0.01% 354
2021
Q1 		$1K Buy
+365
New +$1.24K ﹤0.01% 359

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MWM
Meridian Wealth Management Lexington, Kentucky $3.25B AUM 41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Burleson & Co's ACER Position: Q4 2022 in Review

Burleson & Co held its Acer Therapeutics Inc (ACER) position steady in Q4 2022 at 365 shares worth $916. The position accounts for ﹤0.01% of the portfolio, ranked #356.

Burleson & Co first reported a position in ACER in Q1 2021 and has held it in 8 quarters since. The position peaked at $1K in Q3 2022. 32 funds tracked by Wall St. Rank hold ACER as of Q4 2022.

  • Burleson & Co held 365 shares of Acer Therapeutics Inc worth $916 as of Q4 2022.
  • Burleson & Co left its Acer Therapeutics Inc share count unchanged in Q4 2022.
  • Acer Therapeutics Inc made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #356 holding.
  • Burleson & Co first reported a position in Acer Therapeutics Inc in Q1 2021 and has held it in 8 quarters since.
  • Burleson & Co's Acer Therapeutics Inc position peaked at $1K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.